Please login to the form below

Not currently logged in
Email:
Password:

Eyevensys

This page shows the latest Eyevensys news and features for those working in and with pharma, biotech and healthcare.

Spark set to file eye disease gene therapy next year

Spark set to file eye disease gene therapy next year

Others include Bristol-Myers Squibb-backed Eyevensys, GenSight Biologics (supported by Novartis), Oxford Biomedica, Avalanche Biotechnologies, Applied Genetic Technologies, and ReGenxbio. .

Latest news

  • Boehringer backs gene therapy firm Eyevensys Boehringer backs gene therapy firm Eyevensys

    Invests in French eye disease specialist.  . Boehringer Ingelheim has announced an equity investment in French gene therapy firm Eyevensys, which specialises in the treatment of eye diseases. ... Eyevensys was set up in 2009 and raised 1.6m in its first

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics